Like the flu vac­cine every year, the FDA could move quick­ly on a vari­ant-tar­get­ed Covid vac­cine

In the same way that the FDA signs off on flu vac­cines every year with­out re­quir­ing large clin­i­cal tri­als to mea­sure their ef­fi­ca­cy, the FDA may em­ploy a sim­i­lar strat­e­gy in au­tho­riz­ing vari­ant-fo­cused ver­sions of the mR­NA vac­cines.

As the world braces for more da­ta on the lat­est vari­ant Omi­cron, which may re­duce vac­cine ef­fi­ca­cy, top vac­cine de­vel­op­ers like Mod­er­na and Pfiz­er-BioN­Tech have promised they can pull to­geth­er a new vac­cine tar­get­ed against a spe­cif­ic Covid vari­ant in about 100 days. Since Omi­cron emerged last week, Pfiz­er-BioN­Tech, Mod­er­na and J&J have all said they’ve be­gun work on Omi­cron-spe­cif­ic vac­cines, if need­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.